We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS - Free Report) reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 38 cents, which beat the Zacks Consensus Estimate of 27 cents by 40.7%. The company also reported earnings of 25 cents per share in the prior-year quarter.
Adjusted EPS for fiscal 2025 was $1.42, up 49.5% year over year.
DOCS registered GAAP net income per share of 31 cents, up from the year-ago quarter’s figure of 20 cents. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)
Revenue Details of Doximity
Total revenues grew 17% to $138.3 million year over year. Sales beat the Zacks Consensus Estimate by 3.4%. The revenue growth was driven by subscription revenues of $131.9 million, up 17% year over year. DOCS’ unique active users on a quarterly, monthly, weekly and daily basis all hit fresh highs in the fiscal fourth quarter. The company’s workflow tools — telehealth, fax, scheduling and AI tools — also hit fresh highs during the quarter with over 620,000 unique active prescribers.
Total revenues in fiscal 2025 rose 20% year over year to $570.4 million. Subscription revenues totaled $543.8 million, up 21% year over year. The company’s net revenue retention rate was 119% on a trailing 12-month basis.
Following the earnings release, shares of DOCS plunged 20.7% during after-hours trading on May 15. The stock fell 9.5% year to date compared with a 6.2% decline in the industry. The broader S&P 500 Index has moved down 0.3% in the same period.
Image Source: Zacks Investment Research
Margin Analysis of DOCS
Adjusted gross profit totaled $126.5 million, up 17.3% from the prior-year quarter’s level. Doximity reported an adjusted gross margin (as a percentage of revenues) of 91.4%, up almost 10 basis points (bps) year over year.
Research and development expenses totaled $24.8 million, up 23.1% year over year. Sales and marketing expenses totaled $37.6 million, up 12.2%. General and administrative expenses totaled $37.6 million, up 27.6%.
The company reported total adjusted operating income of $68 million, up 23.7% from the prior-year period’s recorded number. Adjusted operating margin (as a percentage of revenues) was 49.1%, up 260 bps year over year.
Financial Position of Doximity
DOCS exited the fiscal fourth quarter with cash, cash equivalents, and marketable securities worth $915.7 million compared with $844.9 million in the third quarter of fiscal 2025.
Total assets amounted to $1.26 billion, up sequentially from $1.17 billion.
DOCS’ Fiscal 2026 Guidance
Doximity issued its outlook for fiscal 2026 revenues. The company expects revenues to be between $619 million and $631 million. The Zacks Consensus Estimate was pegged at $627 million.
DOCS expects first-quarter fiscal 2026 sales to be in the range of $139-$140 million. The Zacks Consensus Estimate was pinned at $142.3 million.
Doximity's fiscal fourth-quarter sales and earnings beat estimates, but sales guidance for the first quarter of fiscal 2026 fell short of estimates. However, Platform engagement hit record highs across all user metrics, led by the Newsfeed and growing adoption of AI tools, which rose 5x year over year. Over 620,000 prescribers used Doximity’s workflow tools, including telehealth, fax and scheduling features. AI features, such as document analysis and clinical summarization, central to Doximity GPT, gained traction among physicians.
Doximity is investing heavily in AI to enhance both clinician tools and pharma client solutions. The company’s integrated programs are improving ROI and predictability, while its client portal offers real-time performance and targeting insights.
Zacks Rank and Stocks to Consider
DOCS carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks from the same medical industry are GENEDX HOLDINGS (WGS - Free Report) , CVS Health (CVS - Free Report) and Cencora (COR - Free Report) .
WGS’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 145.82%. WGS’ shares have declined 17.3% so far this year.
CVS Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 12.2% for 2025.
CVS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 18.08%. CVS’ shares have risen 34.7% year to date.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 16.7% for 2025.
COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.00%. Its shares have gained 27.3% so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up
Doximity (DOCS - Free Report) reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 38 cents, which beat the Zacks Consensus Estimate of 27 cents by 40.7%. The company also reported earnings of 25 cents per share in the prior-year quarter.
Adjusted EPS for fiscal 2025 was $1.42, up 49.5% year over year.
DOCS registered GAAP net income per share of 31 cents, up from the year-ago quarter’s figure of 20 cents. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)
Revenue Details of Doximity
Total revenues grew 17% to $138.3 million year over year. Sales beat the Zacks Consensus Estimate by 3.4%. The revenue growth was driven by subscription revenues of $131.9 million, up 17% year over year. DOCS’ unique active users on a quarterly, monthly, weekly and daily basis all hit fresh highs in the fiscal fourth quarter. The company’s workflow tools — telehealth, fax, scheduling and AI tools — also hit fresh highs during the quarter with over 620,000 unique active prescribers.
Total revenues in fiscal 2025 rose 20% year over year to $570.4 million. Subscription revenues totaled $543.8 million, up 21% year over year. The company’s net revenue retention rate was 119% on a trailing 12-month basis.
Following the earnings release, shares of DOCS plunged 20.7% during after-hours trading on May 15. The stock fell 9.5% year to date compared with a 6.2% decline in the industry. The broader S&P 500 Index has moved down 0.3% in the same period.
Image Source: Zacks Investment Research
Margin Analysis of DOCS
Adjusted gross profit totaled $126.5 million, up 17.3% from the prior-year quarter’s level. Doximity reported an adjusted gross margin (as a percentage of revenues) of 91.4%, up almost 10 basis points (bps) year over year.
Research and development expenses totaled $24.8 million, up 23.1% year over year. Sales and marketing expenses totaled $37.6 million, up 12.2%. General and administrative expenses totaled $37.6 million, up 27.6%.
The company reported total adjusted operating income of $68 million, up 23.7% from the prior-year period’s recorded number. Adjusted operating margin (as a percentage of revenues) was 49.1%, up 260 bps year over year.
Financial Position of Doximity
DOCS exited the fiscal fourth quarter with cash, cash equivalents, and marketable securities worth $915.7 million compared with $844.9 million in the third quarter of fiscal 2025.
Total assets amounted to $1.26 billion, up sequentially from $1.17 billion.
DOCS’ Fiscal 2026 Guidance
Doximity issued its outlook for fiscal 2026 revenues. The company expects revenues to be between $619 million and $631 million. The Zacks Consensus Estimate was pegged at $627 million.
DOCS expects first-quarter fiscal 2026 sales to be in the range of $139-$140 million. The Zacks Consensus Estimate was pinned at $142.3 million.
Doximity, Inc. Price, Consensus and EPS Surprise
Doximity, Inc. price-consensus-eps-surprise-chart | Doximity, Inc. Quote
Wrapping Up
Doximity's fiscal fourth-quarter sales and earnings beat estimates, but sales guidance for the first quarter of fiscal 2026 fell short of estimates. However, Platform engagement hit record highs across all user metrics, led by the Newsfeed and growing adoption of AI tools, which rose 5x year over year. Over 620,000 prescribers used Doximity’s workflow tools, including telehealth, fax and scheduling features. AI features, such as document analysis and clinical summarization, central to Doximity GPT, gained traction among physicians.
Doximity is investing heavily in AI to enhance both clinician tools and pharma client solutions. The company’s integrated programs are improving ROI and predictability, while its client portal offers real-time performance and targeting insights.
Zacks Rank and Stocks to Consider
DOCS carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks from the same medical industry are GENEDX HOLDINGS (WGS - Free Report) , CVS Health (CVS - Free Report) and Cencora (COR - Free Report) .
GENEDX, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 336% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
WGS’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 145.82%. WGS’ shares have declined 17.3% so far this year.
CVS Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 12.2% for 2025.
CVS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 18.08%. CVS’ shares have risen 34.7% year to date.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 16.7% for 2025.
COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.00%. Its shares have gained 27.3% so far this year.